Your TMJ Pain Has a Biological Root. Here's What Your Genes Reveal.

COMT is an enzyme that breaks down catecholamines,dopamine, norepinephrine, and epinephrine. These neurotransmitters are critical for pain modulation. When COMT clears them efficiently, your nervous system’s natural pain-dampening signals work smoothly. Your pain threshold remains stable, and acute injuries resolve without evolving into chronic pain.

The Val158Met variant is carried by roughly 25% of people with European ancestry who are homozygous for the slow version. The slow COMT variant dramatically slows catecholamine clearance, meaning pain-modulating signals accumulate slowly in your synapses, leaving you vulnerable to pain amplification. Your nervous system struggles to turn off the pain signal once it’s switched on.

For TMJ pain specifically, this translates into sustained jaw tension, heightened sensitivity to chewing, and difficulty recovering from dental work or jaw trauma. You might notice your TMJ pain worsens with stress, caffeine, or physical exertion, all of which trigger catecholamine release that your slow COMT cannot clear efficiently.

OPRM1 encodes the mu-opioid receptor, which is how your body’s endogenous opioids (endorphins and enkephalins) communicate with your nervous system to suppress pain. This is your built-in analgesia system, running 24/7, especially during exercise, stress, or injury. A well-functioning opioid receptor system means your body can naturally dial down pain without external substances.

The A118G variant (G allele) is carried by roughly 10-15% of people with European ancestry and up to 40% of East Asian ancestry. This variant reduces your mu-opioid receptor’s sensitivity to endogenous opioids, meaning your natural pain-relief system works at a fraction of its normal capacity. Your body is producing endorphins, but they’re not binding to receptors effectively.

With TMJ pain, this means your nervous system lacks the endogenous opioid brake that would normally suppress jaw pain during stress or physical activity. You might notice that exercise, which helps others manage pain, barely touches yours. Your jaw hurts consistently because your natural pain-relief signaling is impaired at the receptor level.

MTHFR catalyzes the conversion of folate into its active form, methylfolate, which is essential for methylation reactions throughout your body. One critical methylation-dependent process is the synthesis of monoamine neurotransmitters, including serotonin and dopamine, both of which modulate pain. Additionally, MTHFR activity affects vascular tone through nitric oxide metabolism, and impaired vascular regulation worsens TMJ pain by increasing muscle tension and reducing blood flow to jaw muscles.

The C677T variant is carried by roughly 40% of people with European ancestry. This variant reduces MTHFR enzyme efficiency by 40-70%, meaning your cells struggle to produce active methylfolate and synthesize adequate pain-modulating neurotransmitters. Your nervous system is biochemically understaffed for pain regulation.

In TMJ pain, MTHFR impairment manifests as heightened pain sensitivity, poor jaw muscle recovery, and pain that worsens with stress or hormonal changes. You might have low serotonin symptoms alongside your jaw pain: mood sensitivity, sleep disruption, and a sense that pain control is simply beyond your nervous system’s capacity.

BDNF is a neurotrophic factor that shapes how pain-processing circuits in your brain are wired and strengthened. High BDNF activity can amplify central sensitization, the process by which your nervous system becomes progressively more sensitive to pain signals. In TMJ pain, this means your pain system isn’t just responding to jaw dysfunction; it’s learning to amplify that signal over time, creating pain memory that persists even after the original injury heals.

The Val66Met variant is carried by roughly 30% of people and associated with altered pain response. The Met allele impairs BDNF secretion, potentially meaning your nervous system struggles to either strengthen pain-inhibition circuits or weaken pain-amplification circuits, leaving you caught between insufficient pain suppression and persistent pain sensitization. Your pain system is unbalanced.

For TMJ pain, BDNF variants mean that acute jaw pain from poor posture or dental work can evolve into chronic pain more easily. Your nervous system doesn’t downregulate the pain signal once the injury heals. Jaw pain becomes your new normal, triggered by progressively smaller mechanical stressors. You might describe it as pain memory: your jaw hurts not because of active damage but because your nervous system learned to hurt.

GCH1 encodes the enzyme that synthesizes tetrahydrobiopterin (BH4), a critical cofactor for multiple pain-regulating neurotransmitters, including serotonin, dopamine, and nitric oxide. BH4 is also required for the production of GTP, which fuels cellular energy. When GCH1 function is impaired, your capacity to synthesize pain-modulating molecules across your entire nervous system declines. Pain sensitivity rises, and your natural pain-relief mechanisms lose their biochemical foundation.

GCH1 variants are carried by roughly 15-20% of the population and are associated with reduced pain tolerance in multiple studies. Reduced GCH1 activity means your neurons cannot manufacture adequate BH4, starving them of the cofactor required for pain modulation and leaving you with a persistently elevated pain threshold. Your nervous system is literally missing a key chemical for pain suppression.

In TMJ pain, GCH1 impairment creates baseline pain sensitivity that makes jaw pain feel more intense and more difficult to suppress. Simple mechanical stressors,chewing, talking, light touch,trigger pain responses that others would barely notice. You might also experience general low pain tolerance in other areas: headaches, neck pain, or generalized body aching alongside your TMJ symptoms.

FAAH breaks down anandamide, an endogenous cannabinoid that acts as a natural analgesic and anxiolytic. Your body produces anandamide in response to pain, stress, and physical activity. FAAH then clears it from your synapses. This cycle normally creates a balanced endocannabinoid tone that keeps pain and anxiety in check. When FAAH clears anandamide too quickly, you lose the analgesic benefit before it can suppress pain signals.

The C385A variant (A allele) is carried by roughly 20-30% of people and reduces FAAH activity. The A allele means your body clears anandamide more slowly, leading to higher baseline anandamide levels and a robust analgesic effect that translates directly into reduced pain sensitivity. You literally have more endogenous pain relief circulating in your nervous system.

Interestingly, people with the FAAH A allele typically experience less TMJ pain and better pain tolerance in general. However, if you carry the opposite variant (CC), you clear anandamide rapidly and lose the analgesic benefit quickly. Your TMJ pain will feel sharper, less responsive to rest or movement, and more resistant to the body’s natural pain suppression. You might also notice that stress and anxiety worsen your pain disproportionately, since anandamide also regulates the anxiety response.